Equities research analysts predict that Aravive, Inc. (NASDAQ:ARAV) will report earnings per share of ($0.45) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aravive’s earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.53). Aravive posted earnings per share of ($0.53) in the same quarter last year, which suggests a positive year over year growth rate of 15.1%. The company is expected to announce its next quarterly earnings report on Wednesday, May 5th.
According to Zacks, analysts expect that Aravive will report full-year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($2.22) to ($1.64). For the next year, analysts expect that the company will report earnings of ($2.12) per share, with EPS estimates ranging from ($2.57) to ($1.73). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Aravive.
Aravive (NASDAQ:ARAV) last posted its quarterly earnings data on Monday, March 15th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.27. The company had revenue of $5.69 million during the quarter.
ARAV has been the subject of a number of research reports. Zacks Investment Research upgraded Aravive from a “sell” rating to a “hold” rating in a research report on Tuesday, February 16th. BTIG Research assumed coverage on shares of Aravive in a report on Monday, March 15th. They issued a “buy” rating and a $26.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Aravive has a consensus rating of “Buy” and an average target price of $21.92.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers acquired a new stake in Aravive during the 4th quarter worth $75,000. Blair William & Co. IL bought a new stake in shares of Aravive in the fourth quarter worth about $203,000. BlackRock Inc. raised its position in shares of Aravive by 3.1% during the fourth quarter. BlackRock Inc. now owns 789,845 shares of the company’s stock worth $4,455,000 after purchasing an additional 23,993 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Aravive during the third quarter worth about $183,000. Finally, Trexquant Investment LP bought a new position in shares of Aravive during the 4th quarter valued at about $105,000. Institutional investors and hedge funds own 40.54% of the company’s stock.
Shares of ARAV stock remained flat at $$5.20 on Friday. The stock had a trading volume of 1,372 shares, compared to its average volume of 211,433. Aravive has a 12 month low of $4.27 and a 12 month high of $14.94. The company has a market capitalization of $102.23 million, a PE ratio of -2.58 and a beta of 3.20. The firm’s 50 day moving average price is $6.56 and its 200 day moving average price is $6.00.
Aravive, Inc, a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer.
Read More: Tariff
Get a free copy of the Zacks research report on Aravive (ARAV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.